Literature DB >> 12890557

The chromosome 21 transcription factor ETS2 transactivates the beta-APP promoter: implications for Down syndrome.

E W Wolvetang1, O M Bradfield, M Tymms, S Zavarsek, T Hatzistavrou, I Kola, P J Hertzog.   

Abstract

The gene that codes for beta-amyloid precursor protein (beta-APP), a protein centrally involved in senile plaque formation in Down syndrome (DS) and Alzheimer's disease (AD), is located on chromosome 21. In DS beta-APP expression is three- to fourfold higher than what is expected from the 1.5-fold increased gene load, suggesting that other genes on chromosome 21 directly or indirectly can further up-regulate beta-APP. Here we show that the chromosome 21 transcription factor ETS2 transactivates the beta-APP gene via specific Ets binding sites in the beta-APP promoter and, in this respect, cooperates with the transcription factor complex AP1. We further show that brains and primary neuronal cultures from Ets2 transgenic mice, as well as 3T3 fibroblasts that overexpress ETS2, display molecular abnormalities also seen in DS, such as elevated expression of beta-APP protein, an increase in presenilin-1 and increased beta-amyloid production. We conclude that ETS2 is a transcriptional regulator of beta-APP and that overexpression of ETS2 in DS may play a role in the pathogenesis of the brain abnormalities in DS and possibly AD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12890557     DOI: 10.1016/s0167-4781(03)00121-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  21 in total

Review 1.  Beta-amyloid modulation of synaptic transmission and plasticity.

Authors:  Deepa V Venkitaramani; Jeannie Chin; William J Netzer; Gunnar K Gouras; Sylvain Lesne; Roberto Malinow; Paul J Lombroso
Journal:  J Neurosci       Date:  2007-10-31       Impact factor: 6.167

Review 2.  mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia.

Authors:  Fabio Di Domenico; Antonella Tramutola; Cesira Foppoli; Elizabeth Head; Marzia Perluigi; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2017-08-12       Impact factor: 7.376

Review 3.  Genetic and epigenetic pathways in Down syndrome: Insights to the brain and immune system from humans and mouse models.

Authors:  Y Eugene Yu; Zhuo Xing; Catherine Do; Annie Pao; Eun Joon Lee; Sharon Krinsky-McHale; Wayne Silverman; Nicole Schupf; Benjamin Tycko
Journal:  Prog Brain Res       Date:  2019-10-24       Impact factor: 2.453

Review 4.  Neurogenetic disorders across the lifespan: from aberrant development to degeneration.

Authors:  Richard A Hickman; Sarah A O'Shea; Mark F Mehler; Wendy K Chung
Journal:  Nat Rev Neurol       Date:  2022-01-05       Impact factor: 42.937

5.  Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model.

Authors:  William J Netzer; Craig Powell; Yi Nong; Jacqueline Blundell; Lili Wong; Karen Duff; Marc Flajolet; Paul Greengard
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

6.  Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes.

Authors:  Claudia D Baldus; Sandya Liyanarachchi; Krzysztof Mrózek; Herbert Auer; Stephan M Tanner; Martin Guimond; Amy S Ruppert; Nehad Mohamed; Ramana V Davuluri; Michael A Caligiuri; Clara D Bloomfield; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-08       Impact factor: 11.205

7.  An Intron 7 Polymorphism in APP Affects the Age of Onset of Dementia in Down Syndrome.

Authors:  Emma L Jones; Clive G Ballard; Vee P Prasher; Matthew Arno; Stephen Tyrer; Brian Moore; Maria Luisa Hanney
Journal:  Int J Alzheimers Dis       Date:  2010-12-20

Review 8.  Animal models of intellectual disability: towards a translational approach.

Authors:  Carla A Scorza; Esper A Cavalheiro
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 9.  A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome.

Authors:  Frances K Wiseman; Tamara Al-Janabi; John Hardy; Annette Karmiloff-Smith; Dean Nizetic; Victor L J Tybulewicz; Elizabeth M C Fisher; André Strydom
Journal:  Nat Rev Neurosci       Date:  2015-08-05       Impact factor: 34.870

10.  Potential contribution of SIM2 and ETS2 functional polymorphisms in Down syndrome associated malignancies.

Authors:  Arpita Chatterjee; Samikshan Dutta; Sanjit Mukherjee; Nupur Mukherjee; Avirup Dutta; Ashis Mukherjee; Swagata Sinha; Chinmay Kumar Panda; Keya Chaudhuri; Ananda L Roy; Kanchan Mukhopadhyay
Journal:  BMC Med Genet       Date:  2013-01-23       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.